Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

Abstract A growing body of evidence supports the presence of a population of cells in glioblastoma (GBM) with a stem cell-like phenotype which shares certain biological markers with adult neural stem cells, including expression of SOX2, CD133 (PROM1), and NES (nestin). This study was designed to det...

Full description

Bibliographic Details
Main Authors: Nelli S. Lakis, Alexander S. Brodsky, Galina Karashchuk, Amanda J. Audesse, Dongfang Yang, Ashlee Sturtevant, Kara Lombardo, Ian Y. Wong, Ashley E. Webb, Douglas C. Anthony
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Acta Neuropathologica Communications
Subjects:
Glioblastoma
Cancer stem cells
SOX2
CD133
MGMT
Online Access:https://doi.org/10.1186/s40478-022-01459-9

Internet

https://doi.org/10.1186/s40478-022-01459-9

Similar Items